Literature DB >> 25869387

Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.

Alexander Filatenkov1, Jeanette Baker2, Antonia M S Mueller2, Justin Kenkel3, G-One Ahn4, Suparna Dutt5, Nigel Zhang5, Holbrook Kohrt5, Kent Jensen5, Sussan Dejbakhsh-Jones5, Judith A Shizuru2, Robert N Negrin2, Edgar G Engleman3, Samuel Strober1.   

Abstract

PURPOSE: The goals of the study were to elucidate the immune mechanisms that contribute to desirable complete remissions of murine colon tumors treated with single radiation dose of 30 Gy. This dose is at the upper end of the ablative range used clinically to treat advanced or metastatic colorectal, liver, and non-small cell lung tumors. EXPERIMENTAL
DESIGN: Changes in the tumor immune microenvironment of single tumor nodules exposed to radiation were studied using 21-day (>1 cm in diameter) CT26 and MC38 colon tumors. These are well-characterized weakly immunogenic tumors.
RESULTS: We found that the high-dose radiation transformed the immunosuppressive tumor microenvironment resulting in an intense CD8(+) T-cell tumor infiltrate, and a loss of myeloid-derived suppressor cells (MDSC). The change was dependent on antigen cross-presenting CD8(+) dendritic cells, secretion of IFNγ, and CD4(+)T cells expressing CD40L. Antitumor CD8(+) T cells entered tumors shortly after radiotherapy, reversed MDSC infiltration, and mediated durable remissions in an IFNγ-dependent manner. Interestingly, extended fractionated radiation regimen did not result in robust CD8(+) T-cell infiltration.
CONCLUSIONS: For immunologically sensitive tumors, these results indicate that remissions induced by a short course of high-dose radiotherapy depend on the development of antitumor immunity that is reflected by the nature and kinetics of changes induced in the tumor cell microenvironment. These results suggest that systematic examination of the tumor immune microenvironment may help in optimizing the radiation regimen used to treat tumors by adding a robust immune response. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25869387      PMCID: PMC4537844          DOI: 10.1158/1078-0432.CCR-14-2824

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  57 in total

1.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes.

Authors:  Edith M Janssen; Edward E Lemmens; Tom Wolfe; Urs Christen; Matthias G von Herrath; Stephen P Schoenberger
Journal:  Nature       Date:  2003-02-09       Impact factor: 49.962

Review 2.  Immunologically augmented cancer treatment using modern radiotherapy.

Authors:  Marco Durante; Norman Reppingen; Kathryn D Held
Journal:  Trends Mol Med       Date:  2013-07-04       Impact factor: 11.951

3.  Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL.

Authors:  Pratima Sinha; Olesya Chornoguz; Virginia K Clements; Konstantin A Artemenko; Roman A Zubarev; Suzanne Ostrand-Rosenberg
Journal:  Blood       Date:  2011-03-30       Impact factor: 22.113

4.  Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

Authors:  Sandra Demaria; Noriko Kawashima; Anne Marie Yang; Mary Louise Devitt; James S Babb; James P Allison; Silvia C Formenti
Journal:  Clin Cancer Res       Date:  2005-01-15       Impact factor: 12.531

5.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.

Authors:  Michael A Curran; Welby Montalvo; Hideo Yagita; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2010-02-16       Impact factor: 11.205

6.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

7.  Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy.

Authors:  Lionel Apetoh; François Ghiringhelli; Antoine Tesniere; Michel Obeid; Carla Ortiz; Alfredo Criollo; Grégoire Mignot; M Chiara Maiuri; Evelyn Ullrich; Patrick Saulnier; Huan Yang; Sebastian Amigorena; Bernard Ryffel; Franck J Barrat; Paul Saftig; Francis Levi; Rosette Lidereau; Catherine Nogues; Jean-Paul Mira; Agnès Chompret; Virginie Joulin; Françoise Clavel-Chapelon; Jean Bourhis; Fabrice André; Suzette Delaloge; Thomas Tursz; Guido Kroemer; Laurence Zitvogel
Journal:  Nat Med       Date:  2007-08-19       Impact factor: 53.440

Review 8.  The contrasting roles of NKT cells in tumor immunity.

Authors:  Jay A Berzofsky; Masaki Terabe
Journal:  Curr Mol Med       Date:  2009-08       Impact factor: 2.222

9.  Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging.

Authors:  Matthias Edinger; Yu-An Cao; Michael R Verneris; Michael H Bachmann; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2002-09-26       Impact factor: 22.113

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  142 in total

Review 1.  The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer.

Authors:  Richard C Walshaw; Jamie Honeychurch; Timothy M Illidge; Ananya Choudhury
Journal:  Nat Rev Urol       Date:  2017-10-31       Impact factor: 14.432

2.  Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma.

Authors:  Anusha Kalbasi; Chad Komar; Graham M Tooker; Mingen Liu; Jae W Lee; Whitney L Gladney; Edgar Ben-Josef; Gregory L Beatty
Journal:  Clin Cancer Res       Date:  2016-06-28       Impact factor: 12.531

3.  Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Authors:  Jennifer E Kim; Mira A Patel; Antonella Mangraviti; Eileen S Kim; Debebe Theodros; Esteban Velarde; Ann Liu; Eric W Sankey; Ada Tam; Haiying Xu; Dimitrios Mathios; Christopher M Jackson; Sarah Harris-Bookman; Tomas Garzon-Muvdi; Mary Sheu; Allison M Martin; Betty M Tyler; Phuoc T Tran; Xiaobu Ye; Alessandro Olivi; Janis M Taube; Peter C Burger; Charles G Drake; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

4.  Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy.

Authors:  Emily Z Keung; Jen-Wei Tsai; Ali M Ali; Janice N Cormier; Andrew J Bishop; B Ashleigh Guadagnolo; Keila E Torres; Neeta Somaiah; Kelly K Hunt; Jennifer A Wargo; Alexander J Lazar; Wei-Lien Wang; Christina L Roland
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

5.  Disruption of evasive immune cell microenvironment in tumors reflects immunity induced by radiation therapy.

Authors:  Alexander Filatenkov; Jeanette Baker; Samuel Strober
Journal:  Oncoimmunology       Date:  2016-02-26       Impact factor: 8.110

6.  The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.

Authors:  Michael Spiotto; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Sci Immunol       Date:  2016-09-30

Review 7.  Radiotherapy and immunotherapy: a beneficial liaison?

Authors:  Ralph R Weichselbaum; Hua Liang; Liufu Deng; Yang-Xin Fu
Journal:  Nat Rev Clin Oncol       Date:  2017-01-17       Impact factor: 66.675

8.  PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation.

Authors:  Megan Morisada; Paul E Clavijo; Ellen Moore; Lillian Sun; Michael Chamberlin; Carter Van Waes; James W Hodge; James B Mitchell; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

9.  Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.

Authors:  Osama Mohamad; Alberto Diaz de Leon; Samuel Schroeder; Andrew Leiker; Alana Christie; Elizabeth Zhang-Velten; Lakshya Trivedi; Saad Khan; Neil B Desai; Aaron Laine; Kevin Albuquerque; Puneeth Iyengar; Yull Arriaga; Kevin Courtney; David E Gerber; Hans Hammers; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

10.  In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.

Authors:  Zachary S Morris; Emily I Guy; David M Francis; Monica M Gressett; Lauryn R Werner; Lakeesha L Carmichael; Richard K Yang; Eric A Armstrong; Shyhmin Huang; Fariba Navid; Stephen D Gillies; Alan Korman; Jacquelyn A Hank; Alexander L Rakhmilevich; Paul M Harari; Paul M Sondel
Journal:  Cancer Res       Date:  2016-05-06       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.